Piper Jaffray analyst Christopher Raymond kept his Neutral rating and $95 price target on Celgene, saying he remains concerned with the upcoming loss of exclusivity for Revlimid, but also sees the company with a “decent catalyst schedule on tap”. Raymond believes that a potentially surprisingly positive luspatercept BELIEVE and MEDALIST readouts this year can generate investor interest, though he still would like more clarity on the company’s “picture” post-Revlimid.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.